Back to search

Article

Dual PROTACs Versus Dual Inhibitors in Oncology: A Medicinal Chemistry and Linker Design Perspective

2026-07-03

Abstract excerpt

<h4>Background: </h4> /Objectives: Cancer resistance, pathway redundancy, and compensatory signaling challenge traditional therapies. Dual-target strategies address this by engaging two disease-relevant proteins within a single molecule. This review compares classical dual inhibitors with dual proteolysis-targeting chimeras (dual PROTACs) to evaluate the therapeutic advantages of degradation over occupancy. <h4>Me...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
50c98c93-2162-5715-9099-4b1c07daf96e
DOI
10.20944/preprints202607.0224.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Dual PROTACs Versus Dual Inhibitors in Oncology: A Medicinal Chemistry and Linker Design PerspectiveDOI 10.20944/preprints202607.0224.v1
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapySemantic proximity
Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?Semantic proximity
Targeting the Interplay of Proteins through PROTACs for the Management of Cancer and Associated DisordersSemantic proximity
New-generation advanced PROTACs as potential therapeutic agents in cancer therapySemantic proximity
Overcoming Cancer Drug Resistance Utilizing PROTAC TechnologySemantic proximity
Targeted Protein Degradation in Lung Cancer: The Emerging Role of PROTAC Technology and E3 LigasesSemantic proximity
Multibody-Enabled Lysosome-Targeting Drug Conjugates for Target Protein Degradation and Combination TherapySemantic proximity
Clinical Translation of Targeted Protein DegradersSemantic proximity
Proteolysis‐targeting chimeras in drug development: A safety perspectiveSemantic proximity
FDA-approved kinase inhibitors in PROTAC design, development and synthesisSemantic proximity
Breaking Bad Proteins – Discovery Approaches and the Road to Clinic for DegradersSemantic proximity
Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent KinaseSemantic proximity
Select a neighboring publication to make it the new centre.